{"filing":{"accession_number":"0001410098-26-000054","cik":"0001410098","ticker":"CRMD","company_name":"CorMedix Inc.","form":"8-K","filing_date":"2026-08-13","report_date":"2026-08-13","primary_document":"crmd-20260813.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1410098/000141009826000054/crmd-20260813.htm"},"events":[{"id":27508,"run_id":25078,"accession_number":"0001410098-26-000054","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"CorMedix issued a press release on August 13, 2026, announcing Q2 2026 financial results including consolidated revenue of $101.9 million, net income of $26.0 million, and adjusted EBITDA of $58.7 million, along with updated full-year 2026 guidance. The disclosure is a standard quarterly earnings announcement furnished as Exhibit 99.1 under Item 2.02, with detailed financial statements and business highlights.","company_name":"CorMedix Inc.","ticker":"CRMD","filing_date":"2026-08-13","form":"8-K","submitted_at":null,"items":[{"id":29084,"accession_number":"0001410098-26-000054","item_number":"2.02","item_title":"Results of Operations and Financial Condition","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"CorMedix issued a press release on August 13, 2026, announcing Q2 2026 financial results including consolidated revenue of $101.9 million, net income of $26.0 million, and adjusted EBITDA of $58.7 million, along with updated full-year 2026 guidance. The disclosure is a standard quarterly earnings announcement furnished as Exhibit 99.1 under Item 2.02, with detailed financial statements and business highlights.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-13T11:33:40.072050+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":29084,"accession_number":"0001410098-26-000054","item_number":"2.02","item_title":"Results of Operations and Financial Condition","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"CorMedix issued a press release on August 13, 2026, announcing Q2 2026 financial results including consolidated revenue of $101.9 million, net income of $26.0 million, and adjusted EBITDA of $58.7 million, along with updated full-year 2026 guidance. The disclosure is a standard quarterly earnings announcement furnished as Exhibit 99.1 under Item 2.02, with detailed financial statements and business highlights.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-13T11:33:40.072050+00:00","company_name":"CorMedix Inc.","ticker":"CRMD","filing_date":"2026-08-13"}]}